^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DS-1123
i
Other names: DS-1123a, DS-1123, DS 1123
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Daiichi Sankyo
Drug class:
FGFR2 inhibitor
Related drugs:
5years
DS-Screen: Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer population. (ASCO-GI 2020)
Moreover, eligible patients for the clinical trials of DS-1123 or DS-8201, which are FGFR2- or HER2-targeting anti-cancer agent respectively, were screened. This study showed insights into the expression status of FGFR2 and HER2 in GC and CRC as a large-scale prospective analysis. Seven patients who had no standard therapy could access exploratory new drug based on targetable agents through this study. Clinical trial information: 163380.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • DS-1123
Share via
